BAROnova, Inc., is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.

BAROnova® recently closed a Series D financing of $36.5 million to continue the clinical development of the TransPyloric Shuttle® weight-loss system.* This technology focuses on potentially slowing a person’s gastric emptying, which is a known mechanism of action for weight loss.  In December 2015, BAROnova began enrolling patients in the ENDObesity® II Study, a twelve-month multicenter pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle.




*The BAROnova TransPyloric Shuttle is not available for sale within the United States or internationally. The TransPyloric Shuttle device and methods of use are covered by various US and foreign patents.